AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31931923
Drug: Topical anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anesthesia (benzocaine gel) without audiovisual distraction (AVD)
Trial: 30040008
Drug: Vestibular Rehabilitation
RxNorm normalized name: Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vestibular Rehabilitation Therapy (VRT) in conjunction with cervical spine therapy
Trial: 30040008
Drug: Vestibular Rehabilitation
RxNorm normalized name: Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vestibular Rehabilitation Therapy (VRT)
Trial: 30040008
Drug: Vestibular Rehabilitation
RxNorm normalized name: Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vestibular Rehabilitation Therapy (VRT) in conjunction with light aerobic exercise
Trial: 30040008
Drug: Cervical spine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical spine therapy alone
Trial: 25413267
Drug: Ropivacaine 0.4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.4% infusion
Trial: 22795925
Drug: Ipragliflozin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipragliflozin (300 mg qd)
Trial: 21165291
Drug: Overall Treatment
RxNorm normalized name: Healthy Kids Overall Health Gummies Soft Chew
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall Treatment Effect (OTE) for EC‐MPS
Trial: 12403858
Drug: Home-based asthma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based asthma education program (8 weekly sessions)
Trial: 10547391
Drug: Fenretinide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenretinide (200 mg/day for 5 years)
Trial: 2179478
Drug: Bacillus Calmette‐Guérin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacillus Calmette‐Guérin (BCG) therapy administered in weekly scarifications up to 3 years
Trial: 3047335
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further therapy (Control group)
Trial: 2179478
Drug: Bacillus Calmette‐Guérin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacillus Calmette‐Guérin (BCG) therapy
Trial: 7471341
Drug: Nifedipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (10 mg buccally)
Trial: 30391194
Drug: Oral selexipag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral selexipag
Trial: 27764781
Drug: Gefitinib 250
RxNorm normalized name: gefitinib 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib 250 mg once daily in combination with thoracic radiotherapy (66 Gy in 6.5 weeks, 2 Gy/day, 5 fractions/week) followed by IV cisplatin and vinorelbine chemotherapy
Trial: 25873050
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron treatment at 6 mg/kg/day plus dietary advice
Trial: 23564916
Drug: n-3FA supplement
RxNorm normalized name: (+/-)-N-methylephedrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3FA supplement
Trial: 18506446
Drug: Low-dose 40
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose 40 mg Depo-Medrol soaked Gelfoam applied over the affected nerve root after discectomy
Trial: 16813586
Drug: Combination pre-operative
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combination pre-operative chemoradiotherapy (CRT)
Trial: 8832772
Drug: ORG-2766 (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORG-2766 (40 mg/day)
Trial: 29978378
Drug: RBE-enriched porridge
RxNorm normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBE-enriched porridge (35 g, including 2 g RBE) with water
Trial: 29978378
Drug: RBE-enriched porridge
RxNorm normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBE-enriched porridge (35 g, including 2 g RBE) with milk
Trial: 29978378
Drug: RBE oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBE oil (2 g)
Trial: 25348594
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment options (endoscopic fundoplication and PPI therapy)
Trial: 23059790
Drug: Intrathecal methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal methylprednisolone acetate (MPA) 60 mg + lidocaine 60 mg
Trial: 23059790
Drug: Lidocaine 60
RxNorm normalized name: Gabapentin;Lidocaine 600 MG; 5% Multiple Routes Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 60 mg only (Control)
Trial: 22093120
Drug: Dornase alpha
RxNorm normalized name: Dornase alpha
DrugBank: Dornase alfa (DB00003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dornase alpha inhaled after airway clearance techniques
Trial: 22093120
Drug: Dornase alpha
RxNorm normalized name: Dornase alpha
DrugBank: Dornase alfa (DB00003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dornase alpha inhaled before airway clearance techniques
Trial: 9166128
Drug: 10 mg/m3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/m3 NMP
Trial: 9166128
Drug: 25 mg/m3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/m3 NMP
Trial: 9166128
Drug: 50 mg/m3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/m3 NMP
Trial: 7702974
Drug: Low-dose dobutamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dobutamine (5 micrograms/kg/min) and isosorbide dinitrate (2 micrograms/kg/min) gated blood pool scintigraphy (GBPS)
Trial: 3312176
Drug: Fluoxetine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (all doses)
Trial: 26359996
Drug: IncobotulinumtoxinA (54
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IncobotulinumtoxinA (54 to 64 U administered: GFL 20 U; HFL 10-20 U; LPL 24 U)
Trial: 14583744
Drug: CBD (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD (400 mg)
Trial: 18571340
Drug: Psychosocial therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychosocial therapies
Trial: 15494910
Drug: Single 500-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 500-mg dose of azithromycin
Trial: 15494910
Drug: 1-week course
RxNorm normalized name: ESTRADIOL BENZOATE 1 kg in 1 kg POWDER [Estradiol Benzoate Coarse Grade]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-week course of daily 200-mg dose of doxycycline
Trial: 11032403
Drug: Twice-a-day IFN-beta
RxNorm normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-a-day IFN-beta injection (3 MU i.v. twice a day for 2 weeks)
Trial: 11032403
Drug: Once-a-day IFN-beta
RxNorm normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once-a-day IFN-beta injection (6 MU daily)
Trial: 11032403
Drug: Twice-a-day IFN-beta
RxNorm normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-a-day IFN-beta injection
Trial: 3904894
Drug: Ioxaglate (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ioxaglate (200 mg iodine/ml)
Trial: 30287610
Drug: Medication reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication reduction (stopping one antihypertensive medication) with optional self-monitoring
Trial: 25046730
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of melatonin in soft gel capsules
Trial: 25046730
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg of melatonin powder
Trial: 20362711
Drug: Intravenous abciximab
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous abciximab application during PCI
Trial: 20362711
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of abciximab for 12 hours post-PCI
Trial: 16699827
Drug: Caffeine and
RxNorm normalized name: caffeine and sodium benzoate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine and taurine pills
Trial: 12816784
Drug: 20 mg/d
RxNorm normalized name: Valtoco, 20 mg/dose nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/d iron supplement (ferrous sulfate)
Trial: 9097068
Drug: 8-week depression
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 8-week depression treatment trial
Trial: 9097068
Drug: Additional courses
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional courses of antidepressant therapy
Trial: 8200383
Drug: Adjuvant progestagen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant progestagen therapy
Trial: 17468819
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral and intravenous antimicrobial prophylaxis
Trial: 29654027
Drug: Intravenous antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous antibiotic prophylaxis alone
Trial: 27741344
Drug: Dapsone gel,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapsone gel, 7.5% (3 formulations: DAP-11078, DAP-11079, DAP-11080), applied once daily
Trial: 27741344
Drug: Dapsone gel,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapsone gel, 5%, applied twice-daily
Trial: 27741344
Drug: All dapsone
RxNorm normalized name: Dapsone
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All dapsone formulations (7.5% and 5%)
Trial: 24943000
Drug: Empagliflozin (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin (both doses pooled)
Trial: 23031516
Drug: Cu supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cu supplementation (15 mg Cu sulphate/kg dry matter)
Trial: 18448618
Drug: Intranasal dose
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dose of 10(7) fluorescent focus units (FFU) of a live attenuated influenza virus vaccine (CAIV‐T)
Trial: 18448618
Drug: Commercial inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercial inactivated influenza virus vaccine
Trial: 11864918
Drug: Postmenopausal hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postmenopausal hormone treatment
Trial: 11864918
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no hormone treatment)
Trial: 10408993
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of beta lactam antibiotics and erythromycin
Trial: 10408993
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of clindamycin, tetracycline, trimethoprim/sulfamethoxazole, and ciprofloxacin
Trial: 10408993
Drug: Hospitalized patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospitalized patients receiving multiple drugs
Trial: 7749974
Drug: Diphenhydramine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenhydramine (50 mg), Diphenhydramine (25 mg), Chlorpheniramine (4 mg)
Trial: 7749974
Drug: Diphenhydramine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenhydramine (50 mg) vs Chlorpheniramine (4 mg)
Trial: 2210597
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg isosorbide dinitrate in sustained-release form
Trial: 6171572
Drug: Human leukocyte
RxNorm normalized name: Human leukocyte antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human leukocyte interferon (HLI) at a daily dose of 10(6) units applied by contraceptive pessary technique for 14 days in patients with viral alterations and 21 days in those with changed cytologic findings.
Trial: 6205924
Drug: Propafenon (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenon (300 mg three times daily)
Trial: 6205924
Drug: Dihydroquinidine Chloride
RxNorm normalized name: Hydroquinidine
DrugBank: Hydroquinidine (DB15300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroquinidine Chloride (300 mg six times daily)
Trial: 29277963
Drug: Reactive gel
RxNorm normalized name: MedActive Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reactive gel mattress
Trial: 22935526
Drug: Clopidogrel loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel loading dose 600 mg
Trial: 22935526
Drug: Clopidogrel loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel loading dose 300 mg
Trial: 17953950
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of oral nimesulide
Trial: 17117562
Drug: Synthetic auricular
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic auricular point therapy (blood‐letting on the ear back, point injection of own blood, pricking ear point)
Trial: 9553237
Drug: Lidocaine 60
RxNorm normalized name: Gabapentin;Lidocaine 600 MG; 5% Multiple Routes Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 60 mg
Trial: 15333400
Drug: Ropivacaine 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 15 mg
Trial: 12594142
Drug: Levobupivacaine 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 10 mg
Trial: 10668837
Drug: Sustained-release nifedipine
RxNorm normalized name: nifedipine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release nifedipine
Trial: 1422320
Drug: Ipriflavone (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipriflavone (600 mg/day)
Trial: 4074607
Drug: Conventional metoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional metoprolol 200 mg
Trial: 4074607
Drug: Long-acting metoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting metoprolol 200 mg
Trial: 31420920
Drug: High-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose aspirin (dual COX inhibition)
Trial: 31420920
Drug: Standard low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard low-dose aspirin (selective COX-1 inhibition)
Trial: 28204882
Drug: Vaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal misoprostol 50 µg
Trial: 22640229
Drug: Vaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal misoprostol 25 µg
Trial: 15942186
Drug: Fluoride varnish
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride varnish treatment twice a year at 6-month intervals
Trial: 15942186
Drug: Fluoride varnish
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride varnish treatment 3 times a year within 1 week
Trial: 15942186
Drug: Fluoride varnish
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride varnish treatment 8 times per year during semesters with 1-month intervals
Trial: 15942186
Drug: Fluoride varnish
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride varnish treatment once a year
Trial: 12952112
Drug: Fexofenadine hydrochloride
RxNorm normalized name: Fexofenadine Hydrochloride
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fexofenadine hydrochloride (180 mg)
Trial: 12589354
Drug: Levocetirizine dihydrochloride
RxNorm normalized name: Levocetirizine Dihydrochloride
DrugBank: Levocetirizine (DB06282)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levocetirizine dihydrochloride (5 mg)
Trial: 8991237
Drug: Combined yellow
RxNorm normalized name: yellow OB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined yellow fever and measles vaccines
Trial: 8991237
Drug: Yellow fever
RxNorm normalized name: yellow fever live
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yellow fever vaccine administered separately
Trial: 8991237
Drug: Measles vaccine
RxNorm normalized name: Measles vaccine
DrugBank: Measles virus vaccine live attenuated (DB10315)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measles vaccine administered separately
Trial: 29948103
Drug: Overnight treatment
RxNorm normalized name: Dermarest Psoriasis Overnight Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overnight treatment with the occlusive intensive patch (OIP) containing Allium cepa extract and allantoin for 12-24 weeks
Trial: 29948103
Drug: Overnight treatment
RxNorm normalized name: Dermarest Psoriasis Overnight Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overnight treatment with the occlusive intensive patch (OIP)
Trial: 26329980
Drug: Atomoxetine (40-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine (40-100 mg/day)
Trial: 18193377
Drug: Phytosterol enriched
RxNorm normalized name: phytosterols
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytosterol enriched drinkable yogurt (1.6 g of free sterol equivalents)
Trial: 11140432
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone propionate (FP) administered via dry powder and metered-dose inhalers
Trial: 8872851
Drug: Initial treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial treatment with felodipine
Trial: 8872851
Drug: Low-dose felodipine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose felodipine
Trial: 8872851
Drug: High-dose felodipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose felodipine plus additional drugs
Trial: 1511150
Drug: Monthly performance
RxNorm normalized name: Perform
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly performance overviews comparing individual doctors to peers
Trial: 6595452
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A supplementation (10,000 IU daily)
Trial: 30554409
Drug: High serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High serum levels of NOx over 70 µmol/L
Trial: 30554409
Drug: High serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High serum levels of NOx over 70 µmol/L in men
Trial: 25541919
Drug: Citicoline (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citicoline (500 mg every 6 hours) intravenously for fifteen days
Trial: 19947262
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment at Shenshu (BL 23), Guanyuan (CV 4), Taixi (KI 3), Sanyinjiao (SP 6) for 12 weeks
Trial: 19947262
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of Polyene Phosphatidylcholine Capsules for 12 weeks
Trial: 12017408
Drug: Gemifloxacin 320
RxNorm normalized name: gemifloxacin 320 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemifloxacin 320 mg once daily for 5 days
Trial: 15277269
Drug: Study recommendations
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study recommendations for boost radiation treatment
Trial: 15277269
Drug: Stated policy
RxNorm normalized name: Polivy
DrugBank: Polatuzumab vedotin (DB12240)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Stated policy for boost radiation treatment
Trial: 11455677
Drug: Enteric coated
RxNorm normalized name: Mesasal Enteric Coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric coated formulation containing 90 mg peppermint oil and 50 mg caraway oil (test)
Trial: 11455677
Drug: Immediate release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release formulation containing 36 mg peppermint oil and 20 mg caraway oil (reference)
Trial: 11455677
Drug: Enteric coated
RxNorm normalized name: Mesasal Enteric Coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric coated formulation (test)
Trial: 11455677
Drug: Immediate release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release formulation (reference)
Trial: 9744605
Drug: Sublingual hyoscyamine
RxNorm normalized name: hyoscyamine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual hyoscyamine (0.125 mg/tablet, 2 tablets)
Trial: 7799699
Drug: Inhaled sodium
RxNorm normalized name: Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled sodium cromoglycate
Trial: 30690687
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (n=1113)